Should You Get a Galleri Test? What the Evidence Actually Shows

The Galleri test — a liquid biopsy that screens for over 50 cancer types from a single blood draw — has become one of the most talked-about tools in proactive health circles. At $949 per test and not covered by insurance, it’s also one of the most expensive screening decisions you can make. So what does the evidence actually show?

At Protocol, we grade every screening recommendation against published data. Galleri currently earns an evidence grade of [C] — expert inference only, with no randomized controlled trial (RCT) evidence that it reduces cancer deaths. That doesn’t make it useless. It means you need to understand exactly what it can and can’t do before writing the check.

How the Galleri Test Works

Galleri detects cell-free DNA — fragments of genetic material that tumors shed into the bloodstream. By analyzing methylation patterns on that DNA, the test identifies signals associated with specific cancer types. The concept is straightforward: catch cancer early through a routine blood draw, before symptoms appear.

The promise is real. Multi-cancer early detection (MCED) is a legitimate field of research with major investment from GRAIL (the company behind Galleri), academic medical centers, and the UK’s National Health Service.

But promise and proof are different things.

The Sensitivity Problem: Stage Matters

Sensitivity — the test’s ability to correctly identify someone who has cancer — varies dramatically by stage. Data from the CCGA (Circulating Cell-free Genome Atlas) study:

• Stage I cancers: 16.8% sensitivity
• Stage II cancers: 40.4% sensitivity
• Stage III cancers: 77% sensitivity
• Stage IV cancers: 90.1% sensitivity

Read those numbers carefully. For stage I cancers — the ones you most want to catch early — the test detects fewer than 1 in 5. It performs best at finding cancers that are already advanced, which is the opposite of what most people assume when they hear “early detection.”

The test isn’t broken. The biology is hard. Early-stage tumors shed less cell-free DNA, making detection inherently more difficult. But anyone considering this test needs to understand that a negative Galleri result provides limited reassurance about early-stage disease.

False Positives: The PATHFINDER Study

The PATHFINDER study enrolled approximately 6,600 adults aged 50 and older to evaluate Galleri in a real-world clinical setting. Among those who received a positive result, approximately 30% turned out to be false positives — meaning the test flagged cancer that wasn’t there.

A false positive on a cancer screening test is not a minor inconvenience. It triggers follow-up imaging, biopsies, specialist referrals, and weeks or months of anxiety. For a test that costs $949 out of pocket, a 30% false positive rate among positives is a data point you need to weigh seriously.

The overall specificity — its ability to correctly identify people without cancer — is high, around 99.5%. That sounds reassuring until you consider the math of screening large populations where cancer prevalence is low. Even small false positive rates translate to a lot of unnecessary workups when you’re screening millions of people.

The NHS-Galleri Trial: A Cautionary Signal

The UK’s National Health Service launched a large-scale trial of the Galleri test to determine whether it could reduce late-stage cancer diagnoses at a population level. This was one of the most important real-world evaluations of the technology.

The trial was recently paused due to poor clinical performance. Details are still emerging, but the pause itself matters. The NHS is one of the most rigorous evaluators of screening interventions in the world. When they pause a trial, the evidence community pays attention.

The technology isn’t dead. But the current version of the test, in its current form, did not meet the bar for population-level screening in a system that demands proof of clinical benefit.

What Evidence Grade [C] Means

Protocol uses a three-tier evidence grading system for all screening recommendations:

• [A] — RCT evidence for mortality reduction. The gold standard. Colonoscopy for colorectal cancer, mammography for breast cancer, and low-dose CT for lung cancer in eligible smokers all meet this bar.
• [B] — Observational evidence supporting benefit. Strong data, but not from randomized trials.
• [C] — Expert inference only. Biologically plausible, mechanistically sound, but no direct evidence that the intervention reduces cancer deaths.

Galleri is [C]. There are no completed RCTs showing that Galleri screening reduces cancer mortality. The sensitivity data is real, the biology is sound, but the question that actually matters — does this test save lives? — remains unanswered.

For context, PSA screening for prostate cancer spent decades at a similar evidence level before large RCTs clarified its benefits and harms. Evidence grades change as data accumulates. [C] today does not mean [C] forever.

What Galleri Can Do

• Detect cancers that have no current guideline-based screening test (pancreatic, ovarian, liver, and others)
• Identify the tissue of origin with reasonable accuracy, helping direct diagnostic workup
• Complement — not replace — existing screening for cancers that do have [A]-level screening protocols
• Provide data for individuals at very high risk who want maximum surveillance

What Galleri Cannot Do

• Replace guideline-based screening. Galleri does not eliminate the need for colonoscopy, mammography, low-dose CT, or other [A]-level screening tests.
• Provide reliable reassurance for early-stage disease. A negative result does not mean you are cancer-free. With 16.8% sensitivity for stage I, the test misses more than 4 out of 5 early cancers.
• Demonstrate mortality benefit. No RCT has shown that Galleri screening leads to fewer cancer deaths.
• Justify skipping risk-factor modification. Even if you test negative, the modifiable risk factors that drive 40% of cancers still apply.

Protocol’s Approach: Risk Tiers First

Our Cancer Prevention protocol (Protocol 9) starts with what we know works: a three-tier risk stratification system based on your family history, genetic risk factors, and modifiable exposures. This determines which [A]-level screening tests you need, how often, and starting at what age.

For someone in Tier 1 (average risk) with no family history and no notable risk factors, the evidence does not support Galleri as a routine annual screen. The false positive rate, the cost, and the limited early-stage sensitivity make it a poor value proposition compared to investing in screenings that have proven mortality benefit.

For someone in Tier 3 (high risk) — a first-degree relative diagnosed before 50, a known BRCA1/2 or Lynch syndrome variant, or a personal cancer history — the math changes. These individuals already face elevated baseline risk, and cancers without established screening protocols (pancreatic cancer in Lynch syndrome carriers, for example) represent real gaps in their surveillance plan. For this population, Galleri may be a reasonable supplement to an already aggressive screening program.

The key word is supplement. Galleri does not replace anything in a risk-tiered screening plan. It adds a layer of surveillance for cancers that lack better options.

The Cost Question

At $949 per test, with annual repeat testing recommended by GRAIL, Galleri is a $949/year ongoing expense with no insurance coverage. Over a decade, that’s nearly $10,000 — not including the costs of follow-up workups triggered by positive or indeterminate results.

Compare that to a screening colonoscopy every 10 years (typically covered by insurance), which has [A]-level RCT evidence for reducing colorectal cancer mortality. Dollar for dollar, evidence-based screening delivers more proven value.

This is not an argument against spending money on health. It’s an argument for spending it where the evidence is strongest first, and adding experimental tools only after the foundation is solid.

So, Should You Get One?

Galleri is a promising technology that is not ready for routine use. The sensitivity data is underwhelming for early-stage cancers, the NHS trial pause is a real signal, and no RCT demonstrates mortality reduction.

It’s not worthless, either. For high-risk individuals with cancers that lack established screening protocols, it fills a genuine gap. For everyone else, it’s a $949 bet on a technology that may prove transformative in future iterations but currently earns a [C] evidence grade.

Protocol’s recommendation: build your screening plan on [A]-level evidence first. Know your risk tier. Get your colonoscopy, your mammogram, your low-dose CT if you’re eligible. Address the modifiable risk factors — insulin, inflammation, body composition, alcohol, physical activity — that drive 40% of all cancers. Then, if Galleri adds meaningful value to your specific risk profile, consider it as an add-on.

If you want help building a screening plan matched to your actual risk factors — not a one-size-fits-all test — that’s exactly what our Cancer Prevention protocol does.

---

Ready to build a cancer screening plan based on your actual risk profile? Book a Discovery Call to learn how Protocol’s evidence-graded approach matches screening intensity to your specific risk tier.